# Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

> **NCT05583188** · PHASE4 · TERMINATED · sponsor: **Galvanize Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DEVICE:** Aliya Pulsed Electric Fields (PEF) ablation
- **DRUG:** Nivolumab plus Platinum Doublet Chemotherapy
- **DRUG:** Standard of care neoadjuvant therapy
- **OTHER:** Surgical Resection

## Key facts

- **NCT ID:** NCT05583188
- **Lead sponsor:** Galvanize Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-01
- **Primary completion:** 2024-02-08
- **Final completion:** 2024-03-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Strategic
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583188, "Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05583188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*